Abstract
The RAS/RAF/MEK/ERK signaling pathway has been a major clinical focus in oncology research in recent years. A clearer association of B-RAF mutations to cancers such as melanoma, papillary thyroid cancer and others has brought an increasing interest in chemotherapeutics that target this cellular signaling pathway. In this review, the authors summarize the current understanding of science and therapeutic use of the MEK inhibitors targeting the RAS/RAF/ MEK/ERK pathway. Clinical progresses of PD0325901 and AZD6244 are highlighted in addition to developments of new MEK inhibitors. Recently disclosed MEK inhibitors in two sub-divided classes, ATP noncompetitive and ATP competitive inhibitors are discussed.
Keywords: MEK inhibitors, RAF kinase, B-RAF mutation, MEK kinase, PD0325901, AZD6244, hypothemycin, resorcylic acid lactones
Current Topics in Medicinal Chemistry
Title: Recent Advances of MEK Inhibitors and Their Clinical Progress
Volume: 7 Issue: 14
Author(s): Wang John (Yuan), Wilcoxen M. Keith, Nomoto Kenichi and Wu Sara
Affiliation:
Keywords: MEK inhibitors, RAF kinase, B-RAF mutation, MEK kinase, PD0325901, AZD6244, hypothemycin, resorcylic acid lactones
Abstract: The RAS/RAF/MEK/ERK signaling pathway has been a major clinical focus in oncology research in recent years. A clearer association of B-RAF mutations to cancers such as melanoma, papillary thyroid cancer and others has brought an increasing interest in chemotherapeutics that target this cellular signaling pathway. In this review, the authors summarize the current understanding of science and therapeutic use of the MEK inhibitors targeting the RAS/RAF/ MEK/ERK pathway. Clinical progresses of PD0325901 and AZD6244 are highlighted in addition to developments of new MEK inhibitors. Recently disclosed MEK inhibitors in two sub-divided classes, ATP noncompetitive and ATP competitive inhibitors are discussed.
Export Options
About this article
Cite this article as:
John (Yuan) Wang, Keith M. Wilcoxen, Kenichi Nomoto and Sara Wu, Recent Advances of MEK Inhibitors and Their Clinical Progress, Current Topics in Medicinal Chemistry 2007; 7 (14) . https://dx.doi.org/10.2174/156802607781696837
DOI https://dx.doi.org/10.2174/156802607781696837 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Applications for Ligands of Retinoid Receptors
Current Pharmaceutical Design Apolipoprotein E Knockout Models
Current Pharmaceutical Design Development of Medical Images in Differentiating Benign from Malignant Thyroid Nodules
Current Medical Imaging Specific Targeting of Engineered Nanoparticles to Activated Macrophages
Current Nanoscience Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer
Clinical Cancer Drugs Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Current Cancer Drug Targets The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Development of Cancer Vaccine Targeting WT1 Product which is Expressed in Various Kinds of Malignant Neoplasms
Medicinal Chemistry Reviews - Online (Discontinued) Meet Our Editorial Board Member
Endocrine, Metabolic & Immune Disorders - Drug Targets CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes
Current Drug Targets Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery The Role of Heme Oxygenase-1 in T Cell-Mediated Immunity: The All Encompassing Enzyme
Current Pharmaceutical Design Retinoids: Impact on Adiposity, Lipids and Lipoprotein Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Different Treatment Strategies for Pediatric Brain Tumors
Current Pediatric Reviews Time Dependent Distribution of MicroRNA 144 after Intravenous Delivery
MicroRNA Metal Release from and Sequestration by Metallothioneins Monitored by Electrochemistry and SPR
Current Pharmaceutical Biotechnology Commentary: A Myriad Aberrations on Information of Ontogeny of Drug Metabolizing Enzymes in the Pediatric Population: An Obstacle for Personalizing Drug Therapy in the Pediatric Population
Drug Metabolism Letters Pharmacological Treatment of Obstructive Sleep Apnea
Current Pharmaceutical Design Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design